Lanean...
CART Cell Toxicities: New Insight into Mechanisms and Management
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refractory hematologic malignancies. Despite recent clinical suc...
Gorde:
| Argitaratua izan da: | Clin Hematol Int |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Atlantis Press
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7785104/ https://ncbi.nlm.nih.gov/pubmed/33409484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2991/chi.k.201108.001 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|